ClinicalTrials.gg

Program

momelotinib

Also written as “Momelotinib”, “Momelotinib (MMB)” and “MMB”.

Its studies are mostly in Primary Myelofibrosis · Myelodysplastic Syndromes · Polycythemia Vera · Carcinoma, Non-Small-Cell Lung, led by GlaxoSmithKline.

Furthest: phase 3, since Oct 22, 201317 company-led studies, 4 open or runningNext primary completion: Dec 11, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline174 open or runningphase 3since Oct 22, 2013Jul 7, 2009Dec 11, 2026phase 2 · NCT03441113

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Jul 7, 2009.

  1. Jul 7, 2011Phase 2 study in Primary MyelofibrosisNCT01423058 · 61 enrolled · United States, Canada
  2. Oct 22, 2013Phase 3 study in Primary MyelofibrosisNCT01969838 · 432 enrolled · United States, Australia, Austria and more
  3. Nov 25, 2013Phase 2 study in Polycythemia VeraNCT01998828 · 39 enrolled · United States, Australia, Canada and more
  4. Mar 28, 20142 phase 3 studiesNCT02101268, NCT02101021
  5. Apr 24, 2014Phase 2 study in Primary MyelofibrosisNCT02124746 · 87 enrolled · United States, Australia, Canada and more
  6. Jul 30, 2014Phase 1 study in EGFR Mutated EGFR TKI Naive Metastatic NSCLCNCT02206763 · 11 enrolled · United States
  7. Sep 17, 2014Phase 1 study in RecurrenceNCT02244489 · 16 enrolled · United States
  8. Oct 3, 2014Phase 1 study in Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung CancerNCT02258607 · 21 enrolled · United States
  9. Aug 3, 2015Phase 2 study in Primary MyelofibrosisNCT02515630 · 41 enrolled · United States, Canada
  10. Feb 15, 2018Phase 2 study in Primary MyelofibrosisNCT03441113 · 237 enrolled · United States, Australia, Austria and more
  11. Nov 20, 2019Phase 3 study in Primary MyelofibrosisNCT04173494 · 195 enrolled · United States, Australia, Austria and more
  12. Jul 19, 2024Phase 2 study in Primary MyelofibrosisNCT06517875 · 68 planned · United States, Canada, France and more
  13. Feb 21, 2025Phase 2 study in Myelodysplastic SyndromesNCT06847867 · 80 planned · United States, Canada, France and more
  14. Apr 28, 2026Phase 3 study in VEXAS syndromeNCT07569081 · 136 planned

Ahead

  1. Dec 11, 2026Primary completion: phase 2 study in Primary MyelofibrosisNCT03441113
  2. Mar 16, 2027Primary completion: phase 2 study in Primary MyelofibrosisNCT06517875
  3. Jul 14, 2027Primary completion: phase 2 study in Myelodysplastic SyndromesNCT06847867
  4. Dec 6, 2028Primary completion: phase 3 study in VEXAS syndromeNCT07569081

TargetBeta

“The dihydrochloride salt form of momelotinib, an orally bioavailable small molecule inhibitor of wild-type (WT) Janus kinases 1 and 2 (JAK1/2), the JAK2 mutant form JAK2V617F, and activin A receptor type 1 (ACVR1; activin receptor like kinase 2; ALK2), with antineoplastic activity”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07569081VEXAS syndrome3Not yet recruitingDec 6, 2028136
NCT06847867Myelodysplastic Syndromes · United States, Canada, France and more2RecruitingJul 14, 202780
NCT06517875Primary Myelofibrosis · United States, Canada, France and more2RecruitingMar 16, 202768
NCT04173494Primary Myelofibrosis · United States, Australia, Austria and more3CompletedDec 3, 2021195
NCT03441113Primary Myelofibrosis · United States, Australia, Austria and more2Active, not recruitingDec 11, 2026237
NCT02515630Primary Myelofibrosis · United States, Canada2CompletedJul 18, 201741
NCT02258607Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer · United States1TerminatedJul 19, 201621
NCT02244489Recurrence · United States1TerminatedMar 8, 201716
NCT02206763EGFR Mutated EGFR TKI Naive Metastatic NSCLC · United States1TerminatedJan 12, 201711
NCT02124746Primary Myelofibrosis · United States, Australia, Canada and more2CompletedDec 6, 201887
NCT02101268Primary Myelofibrosis · United States, Canada, France and more3CompletedJul 28, 2016156
NCT02101021Metastatic Pancreatic Ductal Adenocarcinoma · United States3TerminatedApr 10, 201725
NCT01998828Polycythemia Vera · United States, Australia, Canada and more2TerminatedMar 17, 201539
NCT01969838Primary Myelofibrosis · United States, Australia, Austria and more3CompletedSep 12, 2016432
NCT01423058Primary Myelofibrosis · United States, Canada2CompletedJun 201461
NCT01236638Primary Myelofibrosis · United States, Australia, Canada2CompletedJun 2014120
NCT00935987Primary Myelofibrosis · United States, Australia, Canada2CompletedApr 2012166

How it is read

Names in the registry

  • “Momelotinib”, 12 entries
  • “Momelotinib (MMB)”, 3 entries
  • “MMB”, 1 entry
  • “CYT387”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.